GlassScriptPhysician profile
Aaron Wyatt
NPI 1811578305
$837.06
in general payments reported to CMS, 2019-2025
24 companies · $89.32 in 2025
The $89.32 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $106 · 2022: $244 · 2023: $119 · 2024: $279 · 2025: $89.32.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $487.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $487.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $182.53 | 2021-2025 | |
| Phathom Pharmaceuticals, INC. | $54.97 | 2024 | Voquezna |
| Tris Pharma INC | $54.80 | 2024 | Dyanavel Xr |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $53.68 | 2021-2025 | Xifaxan |
| Biohaven Pharmaceutical Holding Company LTD. | $44.32 | 2022 | |
| Novo Nordisk INC | $41.15 | 2022-2025 | |
| Corium, LLC | $39.19 | 2023-2024 | Azstarys |
| Boston Scientific Corporation | $37.16 | 2023-2024 | Wavewriter Alpha Prime 16 |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $33.50 | 2024 | Caplyta |
| Lilly USA, LLC | $32.08 | 2022-2025 | Mounjaro |
| Nalu Medical, INC. | $31.82 | 2022 | |
| Janssen Pharmaceuticals, INC | $31.05 | 2022-2023 | Spravato |
| Ironshore Pharmaceuticals INC. | $21.34 | 2023 | Jornay Pm |
| Axsome Therapeutics, INC. | $20.25 | 2024 | Auvelity |
| Nestle Healthcare Nutrition INC. | $20.10 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $19.02 | 2021 | |
| Athena Bioscience, LLC | $17.77 | 2024 | Nexiclon Xr |
| Idorsia Pharmaceuticals US INC | $17.03 | 2024 | Quviviq |
| Alkermes, INC. | $16.54 | 2023 | Lybalvi |
| Seqirus USA INC | $15.95 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $15.71 | 2021 | |
| Supernus Pharmaceuticals, INC. | $14.30 | 2024 | Qelbree |
| Astrazeneca Pharmaceuticals LP | $11.52 | 2021 | |
| Qiagen, LLC | $11.28 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Wyatt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.